T. Afrikanova

发表

De novo loss-of-function mutations in CHD2 cause a fever-sensitive myoclonic epileptic encephalopathy sharing features with Dravet syndrome.

Holger Lerche, Renzo Guerrini, Christel Depienne, 2013, American journal of human genetics.

Identification of GSK-3 as a Potential Therapeutic Entry Point for Epilepsy.

F. van Leuven, A. Crawford, P. D. de Witte, 2018, ACS chemical neuroscience.

Anticonvulsant activity of bisabolene sesquiterpenoids of Curcuma longa in zebrafish and mouse seizure models

A. Crawford, Jan Maes, Camila V. Esguerra, 2012, Epilepsy & Behavior.

Validation of the Zebrafish Pentylenetetrazol Seizure Model: Locomotor versus Electrographic Responses to Antiepileptic Drugs

Peter A. M. de Witte, Alexander D. Crawford, A. Crawford, 2013, PloS one.

Analysis of antibiotic resistance markers in Chlamydia trachomatis clinical isolates obtained after ineffective antibiotic therapy

V. Govorun, M. M. Shkarupeta, V. N. Lazarev, 2007, Bulletin of Experimental Biology and Medicine.

Insights from Zebrafish and Mouse Models on the Activity and Safety of Ar-Turmerone as a Potential Drug Candidate for the Treatment of Epilepsy

W. Dehaen, P. D. de Witte, Camila V. Esguerra, 2013, PloS one.

CHD2 variants are a risk factor for photosensitivity in epilepsy

I. Scheffer, H. Mefford, R. Krause, 2015, Brain : a journal of neurology.

Cross-species pharmacological characterization of the allylglycine seizure model in mice and larval zebrafish

A. Crawford, R. Kaminski, I. Smolders, 2015, Epilepsy & Behavior.

Assessment of the convulsant liability of antidepressants using zebrafish and mouse seizure models

Y. Michotte, A. Crawford, I. Smolders, 2011, Epilepsy & Behavior.

Identification of GSK-3 as a potential drug target for epilepsy via bioactivity analysis of the Congolese medicinal plant Indigofera arrecta

F. Leuven, A. Crawford, I. Smolders, 2019 .